In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Multimodality prediction of life-threatening ventricular arrhythmia in patients with arrhythmogenic cardiomyopathy; a prospective cohort study

Session Arrhythmogenic cardiomyopathy: From pathology to prognosis

Speaker Oyvind Haugen Lie

Congress : ESC Congress 2018

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Myocardial Disease - Clinical: Arrhythmogenic Right Ventricular Cardiomyopathy
  • Session type : Advances in Science
  • FP Number : 5956

Authors : OH Lie (Oslo,NO), C Rootwelt (Oslo,NO), LA Dejgaard (Oslo,NO), IS Leren (Oslo,NO), MK Stokke (Oslo,NO), T Edvardsen (Oslo,NO), KH Haugaa (Oslo,NO)

Authors:
O.H. Lie1 , C. Rootwelt2 , L.A. Dejgaard1 , I.S. Leren2 , M.K. Stokke1 , T. Edvardsen1 , K.H. Haugaa1 , 1Oslo University Hospital, Department of Cardiology, Rikshospitalet, and Center for Cardiological Innovation - Oslo - Norway , 2Center for Cardiological Innovation - Oslo - Norway ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1240

Background: Electrocardiogram (ECG) and cardiac imaging play key roles in the diagnostic criteria for arrhythmogenic cardiomyopathy (AC), but their roles in risk stratification of patients presenting without life-threatening ventricular arrhythmia are unclear.

Purpose: To identify predictors of first-time life-threatening ventricular arrhythmia by assessing clinical characteristics, ECG and cardiac imaging in a prospective cohort study of patients with AC.

Methods: We included consecutive AC probands and mutation positive family members with no previous life-threatening arrhythmic events, and followed them prospectively from time of diagnosis. The endpoint was the first life-threatening ventricular arrhythmia, defined as aborted cardiac arrest, appropriate ICD-shock or sustained ventricular tachycardia. At baseline, we assessed possible risk predictors from three categories; (1) clinical parameters, (2) ECG and (3) cardiac imaging (echocardiography and cardiac magnetic resonance imaging) according to the Task Force Criteria of 2010. In addition to traditional imaging criteria, we assessed left ventricular (LV) and echocardiographic strain parameters. LV mechanical dispersion was defined as the standard deviation of time from onset Q/R on ECG to peak negative strain in 16 LV segments. We recorded exercise habits, and defined high intensity exercise as >6 metabolic equivalents.

Results: We included 117 patients (29% probands, 50% female, age 40±17 years). During 4.2 (IQR 2.4 to 7.4) years of follow-up, 18 (15%) patients experienced life-threatening ventricular arrhythmia. The 1, 2 and 5 year incidence was 6%, 9% and 22%, respectively. History of high intensity exercise was the strongest clinical predictor, T-wave inversions ≥V3 was the strongest ECG predictor and greater LV mechanical dispersion by echocardiography was the strongest predictor from cardiac imaging (adjusted HR; 4.9 [95% CI 1.3–18.3], p=0.02, 5.8 [95% CI 2.1–16.1], p=0.001, and 1.4 [95% CI 1.2–1.6] by 10 ms increments, p<0.001, respectively). These parameters had incremental risk predicting value (Figure, left panel). Arrhythmia free survival in patients with all three risk factors was only 1.2 (95% CI 0.4–1.9) years, compared to 17.4 (95% CI 16.6–18.2) years in patients without any risk factors (Figure, right panel).

Conclusions: History of high intensity exercise, T-wave inversions ≥V3 on ECG and greater echocardiographic LV mechanical dispersion were strong and independent predictors of life-threatening ventricular arrhythmias. AC patients without any of these risk factors had minimal arrhythmic risk, while having more than one risk factor increased the risk dramatically. This may guide decisions on primary preventive ICD implantation in these patients.

Risk prediction model

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are